



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com


AARTI DRUGS LIMITED						
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2013						
PART I (Rs. In Lacs except for share data)						
Sr. No.	Particulars	Quarter Ended			Financial Year Ended	
		31st March, 2013 (Audited)	31st Dec, 2012 (Audited)	31st March, 2012 (Audited)	31st March, 2013 (Audited)	31st March, 2012 (Audited)
1	Income from Operations					
	(a) Gross Sales / Income from Operations	23,647	21,273	21,165	88,575	69,918
	Less : Excise Duty & Sales Tax	1,629	1,424	1,242	6,091	3,992
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	22,018	19,849	19,923	82,484	65,926
	(b) Other Operating Income	18	65	288	91	308
	Total income from operations (net)	22,035	19,913	20,211	82,575	66,234
2	Expenditure					
	(a) Cost of materials consumed	12,722	11,255	9,658	49,244	38,112
	(b) Purchase of stock-in-trade	2,057	2,161	2,480	8,543	7,336
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(188)	(412)	1,884	(2,259)	(92)
	(d) Employee benefits expense	762	774	762	2,853	2,483
	(e) Depreciation and Amortisation Expense	672	654	629	2,598	2,422
	(f) Other expenses	3,160	3,157	2,789	12,161	10,368
	Total expenses	19,185	17,590	18,202	73,140	60,829
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	2,850	2,324	2,009	9,435	5,605
4	Other Income	-	-	-	-	-
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	2,850	2,324	2,009	9,435	5,605
6	Finance costs (interest)	756	749	697	2,804	2,267
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,095	1,574	1,312	6,631	3,338
8	Exceptional Items	43.63	-	116	43.63	116
9	Profit from Ordinary Activities before Tax (7-8)	2,051	1,574	1,195	6,588	3,222
10	Tax Expenses (includes)					
	Provision for Taxation	670	480	454	2,064	976
	Provision for Taxation	590	400	390	1,760	800
	Provision for Deferred Taxation	80	80	64	304	176
11	Net profit from ordinary Activities after Tax (9-10)	1,381	1,094	741	4,524	2,246
12	Paid-up Equity Share Capital of Rs. 10/- each.	1,211	1,211	1,211	1,211	1,211
13	Reserves & Surplus (excluding revaluation reserves)	-	-	-	19,550	16,437
14	Earning per share (of Rs. 10 /- each) (not annualised)					
	Basic & Diluted	11.40	9.04	6.11	37.36	17.84
PART II						
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	-Number of Shares	5,154,122	5,188,057	5,379,245	5,154,122	5,379,245
	-Percentage of Total Shareholding	42.57	42.85	44.43	42.57	44.43
2	Promoters & Promoter Group shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered					
	- Number of Shares	6,954,428	6,920,493	6,729,305	6,954,428	6,729,305
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100	100	100	100	100
	-Percentage of shares(as a % of the total Share capital of the company)	57.43	57.15	55.57	57.43	55.57



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

		Qtr ended 31st March, 2013	
B	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter	0	
	Received during the quarter	2	
	Disposed of during the quarter	2	
	Remaining unresolved at the end of the quarter	0	
STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2013 (Rs. in lacs)			
		For the year ended	
		31/03/2013	31/03/2012
A	EQUITY AND LIABILITIES		
	1 Shareholder' funds		
	(a) Share Capital	1,211	1,211
	(b) Reserves and surplus	19,550	16,437
	A Sub - total - Shareholder's funds	20,761	17,648
	2 Non-current liabilities		
	(a) Long - term borrowings	8,070	6,692
	(b) Deferred tax liabilities (net)	2,751	2,447
	(c) Other long - term liabilities	1,003	771
	(d) Long - term provisions	286	-
	Total - Non - current liabilities	12,111	9,911
	3 Current liabilities		
	(a) Short - term borrowings	21,498	20,557
	(b) Trade payables	13,189	9,379
	(c) Other current liabilities	3,024	2,866
	(d) Short - term provisions	1,389	902
	Total - current liabilities	39,100	33,703
	TOTAL - EQUITY AND LIABILITIES	71,972	61,262
B	ASSETS		
	1 Non-current assets		
	(a) Fixed assets (including CWIP)	30,382	27,653
	(b) Non - current investments	513	692
	(c) Long - term loans and advances	256	227
	Total - Non - current assets	31,151	28,571
	2 Current assets		
	(a) Inventories	14,092	9,791
	(b) Trade receivables	21,567	18,060
	(c) Cash and cash equivalents	288	494
	(d) Short - term loans and advances	1,960	2,715
	(e) Other non - current assets	2,913	1,630
	Total - current assets	40,821	32,691
	TOTAL - ASSETS	71,972	61,262
Notes :			
1 The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 16th May, 2013			
The Board of Directors has recommended a Final Dividend of Rs. 4/-per share on 1,21,08,550 Equity shares of Rs.10/- each fully paid-up for the			
2 Financial year 2012-13.			
3 Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.			
4 Figures for the previous period have been regrouped or rearranged wherever necessary.			
Place : Mumbai		For and on behalf of the Board For AARTI DRUGS LIMITED	
Date: 16th May, 2013		 MR. HARSHIT M. SAVLA (JT. MANAGING DIRECTOR)	

PARIKH JOSHI & KOTHARE (Regd.)

CHARTERED ACCOUNTANTS

49/2341, M. H. B. Colony,
Gandhi Nagar, Bandra (East),
Mumbai 400 051.

Tele: 2645 1439/2651 5396
Fax : 91-22-2645 5867
Email: pjk@mtnl.net.in

Auditor's Report On Quarterly and Annual Financial Results of Aarti Drugs Limited Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors of Aarti Drugs Limited

We have audited the quarterly financial results of Aarti Drugs Limited for the quarter ended 31st March, 2013 and the annual results for the year ended 31st March, 2013 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results have been prepared on the basis of the interim financial statements and annual financial results have been prepared on the basis of the annual financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India and the annual financial statements audited by us.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the annual results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2013 as well as the annual results from 1st April, 2012 to 31st March, 2013.



Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of non promoter shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

**For PARIKH JOSHI & KOTHARE
CHARTERED ACCOUNTANTS**



A handwritten signature in blue ink, appearing to read "Tejas Parikh", written over a horizontal line.

**CA TEJAS PARIKH
PARTNER
M.No. 123215**

Firm Registration No.: 107547W

Mumbai,
Dated: May 16th, 2013